334 related articles for article (PubMed ID: 11287376)
1. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia.
Münchau A; Palmer JD; Dressler D; O'Sullivan JD; Tsang KL; Jahanshahi M; Quinn NP; Lees AJ; Bhatia KP
Brain; 2001 Apr; 124(Pt 4):769-83. PubMed ID: 11287376
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of swallowing function in patients with cervical dystonia undergoing selective peripheral denervation.
Münchau A; Good CD; McGowan S; Quinn NP; Palmer JD; Bhatia KP
J Neurol Neurosurg Psychiatry; 2001 Jul; 71(1):67-72. PubMed ID: 11413266
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
4. Outcome of selective ramisectomy for botulinum toxin resistant torticollis.
Ford B; Louis ED; Greene P; Fahn S
J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):472-8. PubMed ID: 9771768
[TBL] [Abstract][Full Text] [Related]
5. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic.
Cohen-Gadol AA; Ahlskog JE; Matsumoto JY; Swenson MA; McClelland RL; Davis DH
J Neurosurg; 2003 Jun; 98(6):1247-54. PubMed ID: 12816272
[TBL] [Abstract][Full Text] [Related]
6. Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation.
Chawda SJ; Münchau A; Johnson D; Bhatia K; Quinn NP; Stevens J; Lees AJ; Palmer JD
J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):465-71. PubMed ID: 10727482
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type B for cervical dystonia.
Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
[TBL] [Abstract][Full Text] [Related]
8. Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.
Samotus O; Lee J; Jog M
J Neurol; 2018 Jun; 265(6):1269-1278. PubMed ID: 29557988
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Figgitt DP; Noble S
Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
11. Selective peripheral denervation for the treatment of spasmodic torticollis: long-term follow-up results from 648 patients.
Wang J; Li J; Han L; Guo S; Wang L; Xiong Z; Ma J; Liang J; Wang L
Acta Neurochir (Wien); 2015 Mar; 157(3):427-33; discussion 433. PubMed ID: 25616622
[TBL] [Abstract][Full Text] [Related]
12. Selective peripheral denervation for spasmodic torticollis: 13-year experience with 155 patients.
Braun V; Richter HP
J Neurosurg; 2002 Sep; 97(2 Suppl):207-12. PubMed ID: 12296680
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
14. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of selective peripheral denervation in combination with pallidal deep brain stimulation for the treatment of cervical dystonia.
Chung M; Han I; Chung SS; Jang DK; Huh R
Acta Neurochir (Wien); 2015 Mar; 157(3):435-42. PubMed ID: 25471274
[TBL] [Abstract][Full Text] [Related]
16. Selective peripheral denervation for cervical dystonia: long-term follow-up.
Bergenheim AT; Nordh E; Larsson E; Hariz MI
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1307-13. PubMed ID: 25362089
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
Tarsy D
Mov Disord; 1997 Jan; 12(1):100-2. PubMed ID: 8990061
[TBL] [Abstract][Full Text] [Related]
19. The Canadian multicenter trial of pallidal deep brain stimulation for cervical dystonia: preliminary results in three patients.
Kiss ZH; Doig K; Eliasziw M; Ranawaya R; Suchowersky O
Neurosurg Focus; 2004 Jul; 17(1):E5. PubMed ID: 15264774
[TBL] [Abstract][Full Text] [Related]
20. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
